ARA-290, known in the scientific literature as cibinetide, is a small synthetic peptide derived from the structure of erythropoietin (EPO). Helix Bio supplies it strictly for laboratory and academic research use — it is not manufactured, labeled, or sold for human consumption, clinical use, or self-administration, and it is not FDA-approved for any indication. ARA-290 has drawn research interest because it's designed to interact with the innate repair receptor, a receptor complex distinct from the classic erythropoietin receptor that drives red blood cell production. That distinction is why it's often described as a non-hematopoietic EPO analog and why it shows up in published research on tissue protection, nerve fiber biology, and inflammation-related signaling, including third-party clinical research on neuropathic pain and sarcoidosis-associated neuropathy. Helix Bio's ARA-290 ships as a lyophilized powder, is verified through HPLC and mass spectrometry, and includes a certificate of analysis with every batch. This page covers what's known about ARA-290's structure and mechanism, how Helix Bio tests it, and the published research context — useful background before placing a research order.
HPLC certified
Independent analysis
Highest standard
Full traceability
ARA-290 is a short synthetic peptide modeled on a surface region of erythropoietin. Unlike full-length EPO, it's designed not to activate the classic EPO receptor homodimer responsible for red blood cell production, which is the basis for describing it as non-hematopoietic or non-erythropoietic in the literature. Instead, research has focused on its interaction with the innate repair receptor, a complex involving the EPO receptor and CD131 (the beta common receptor).
Third-party sponsors have studied ARA-290 in human clinical trials for conditions including neuropathic pain and sarcoidosis-associated small fiber neuropathy. Those trials are published, third-party clinical research — they are not conducted or sponsored by Helix Bio, and Helix Bio's research-use-only peptide is not the same clinical-grade material used in any trial. ARA-290 is not FDA-approved for any indication in the United States.
Helix Bio provides the specific sequence and batch-level analytical data with order documentation and the certificate of analysis, since exact sequence data matters for citation and protocol accuracy.
Researchers typically request ARA-290 for study designs involving:
ARA-290 from Helix Bio is not sold, marketed, or intended as a drug, supplement, or treatment product, and it is not equivalent to or interchangeable with any clinical-trial or pharmaceutical-grade material.
When you're comparing ARA-290 suppliers, purity you can verify and consistency between batches are what matter most. Helix Bio tests each ARA-290 lot with HPLC and mass spectrometry, then attaches the certificate of analysis to the order so the numbers aren't just a claim on a website.
The peptide ships lyophilized, which holds up better across transit and short-term storage than a pre-dissolved format. Combined with domestic USA manufacturing and shipping, that means shorter transit times and fewer temperature-exposure risks between production and the lab that uses it.
This product is not intended for individual consumers, self-administration, or any use outside a research setting.
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Knowledge Base
Cyclic peptides resist protease degradation and reach undruggable targets. Learn how peptide cyclization works and why stability improves. Explore the research.
How continuous flow, automation, enzymatic routes and AI are changing peptide synthesis technology, and what it means for research peptide purity and supply.
AI now designs peptides from scratch. How AlphaFold 3, RFdiffusion and protein language models reshaped peptide discovery in 2026 — research use only.
